Study of WAL0921 in Patients With Glomerular Kidney Diseases (NCT06466135)
Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria
🩺 Plain-English Summary (8th-Grade Level)
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change disease \[TR MCD\], primary immunoglobulin A nephropathy \[IgAN\], and primary membranous nephropathy \[PMN\]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.
Who can join: Review the eligibility criteria below.
Location: Academic Medical Research Institute — Los Angeles, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (50 Sites)
Showing the first 25 of 50 sites.
- Academic Medical Research Institute — Los Angeles, California
- Colorado Kidney and Vascular Care — Denver, Colorado
- D & H Tamarac Research Center — Tamarac, Florida
- Fides Clinical Research — Atlanta, Georgia
- Nephrology Associates of Northern Illinois and Indiana (NANI) — Hinsdale, Illinois
- Dunes Clinical Research — Dakota Dunes, South Dakota
- Prolato Clinical Research Center — Houston, Texas
- Clinical Trial Network — Houston, Texas
- Clinical Advancement Center — San Antonio, Texas
- Westmead Hospital — Westmead, New South Wales
- Western Health Sunshine Hospital — St Albans, Victoria
- AIIMS Hospital — Raipur, Chhattisgarh
- Muljibhai Patel Urological Hospital — Nadiād, Gujarat
- Dhiraj Hospital — Vadodara, Gujarat
- MS Ramaiah Medical College and Hospitals — Bangalore, Karnataka
- Mazumdar Shah Medical Center — Bangalore, Karnataka
- Manipal Hospital — Pune, Maharashtra
- MGM Medical Care and Hospital — Sambhajinagar, Maharashtra
- Sir Ganga Ram Hospital — New Delhi, National Capital Territory of Delhi
- Max Super Speciality Hospital — Patparganj, National Capital Territory of Delhi
- SUM Hospital — Bhubaneswar, Odisha
- SMS Medical College and Hospital — Jaipur, Rajasthan
- Osmania General Hospital — Hyderabad, Telangana
- Nizam's Institute of Medical Sciences — Hyderabad, Telangana
- Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
📞 Contact the Study Coordinator
Phone: (857) 314-1961
Email: clinicaltrials@waldenbiosciences.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetic Nephropathies
- A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes — Boston, Massachusetts
- Formoterol in Diabetes — Charleston, South Carolina
- Transformative Research in Diabetic Nephropathy — Little Rock, Arkansas
- Transformative Research in Diabetic Nephropathy 2.0 — Philadelphia, Pennsylvania
- Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford, California
Explore by condition: All Diabetic Nephropathies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.